Skip to main content
. 2019 Dec 18;52(2):594–603. doi: 10.4143/crt.2019.493

Fig. 5.

Fig. 5.

Progression-free survival (PFS) per immune-modified Response Evaluation Criteria in Solid Tumor and overall survival (OS) according to the tumor proportion score (TPS) of programmed death ligand-1. Cut-off at 1% (A, B), 20% (C, D), and 50% (E, F). CI, confidence interval.